M&Ms And PBMs: Sandoz CEO Talks Antibiotics And Ustekinumab
Richard Saynor Discusses ‘Offensive’ US Antibiotics Pricing And Reveals Tie-Up For Stelara Rival
At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.
